105 related articles for article (PubMed ID: 11411556)
1. PEGylated recombinant human tumor necrosis factor alpha: pharmacokinetics and anti-tumor effects.
Li YP; Pei YY; Zhou ZH; Zhang XY; Gu ZH; Ding J; Gao XJ; Zhu JH
Biol Pharm Bull; 2001 Jun; 24(6):666-70. PubMed ID: 11411556
[TBL] [Abstract][Full Text] [Related]
2. PEGylated recombinant human tumor necrosis factor alpha: preparation and anti-tumor potency.
Li YP; Pei YY; Ding J; Shen ZM; Zhang XY; Gu ZH; Zhou JJ
Acta Pharmacol Sin; 2001 Jun; 22(6):549-55. PubMed ID: 11747763
[TBL] [Abstract][Full Text] [Related]
3. Stealth polycyanoacrylate nanoparticles as tumor necrosis factor-alpha carriers: pharmacokinetics and anti-tumor effects.
Li YP; Pei YY; Zhou ZH; Zhang XY; Gu ZH; Ding J; Zhou JJ; Gao XJ; Zhu JH
Biol Pharm Bull; 2001 Jun; 24(6):662-5. PubMed ID: 11411555
[TBL] [Abstract][Full Text] [Related]
4. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size.
Fang C; Shi B; Pei YY; Hong MH; Wu J; Chen HZ
Eur J Pharm Sci; 2006 Jan; 27(1):27-36. PubMed ID: 16150582
[TBL] [Abstract][Full Text] [Related]
5. [Influence of particle size and MePEG molecular weight on in vitro macrophage uptake and in vivo long circulating of stealth nanoparticles in rats].
Fang C; Shi B; Hong MH; Pei YY; Chen HZ
Yao Xue Xue Bao; 2006 Apr; 41(4):305-12. PubMed ID: 16856473
[TBL] [Abstract][Full Text] [Related]
6. PEGylated polycyanoacrylate nanoparticles as tumor necrosis factor-alpha carriers.
Li YP; Pei YY; Zhou ZH; Zhang XY; Gu ZH; Ding J; Zhou JJ; Gao XJ
J Control Release; 2001 Apr; 71(3):287-96. PubMed ID: 11295221
[TBL] [Abstract][Full Text] [Related]
7. Chemical modification of natural human tumor necrosis factor-alpha with polyethylene glycol increases its anti-tumor potency.
Tsutsumi Y; Kihira T; Yamamoto S; Kubo K; Nakagawa S; Miyake M; Horisawa Y; Kanamori T; Ikegami H; Mayumi T
Jpn J Cancer Res; 1994 Jan; 85(1):9-12. PubMed ID: 8106293
[TBL] [Abstract][Full Text] [Related]
8. Effect of MePEG molecular weight and particle size on in vitro release of tumor necrosis factor-alpha-loaded nanoparticles.
Fang C; Shi B; Pei YY
Acta Pharmacol Sin; 2005 Feb; 26(2):242-9. PubMed ID: 15663906
[TBL] [Abstract][Full Text] [Related]
9. Effects of recombinant human tumor necrosis factor on rodent gliomas and normal brain.
Kiwit JC; Schmitz KH; Daum L; Reifenberger G; Roosen N
J Neurosurg; 1991 Oct; 75(4):597-603. PubMed ID: 1653310
[TBL] [Abstract][Full Text] [Related]
10. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation.
Tsutsumi Y; Kihira T; Tsunoda S; Kamada H; Nakagawa S; Kaneda Y; Kanamori T; Mayumi T
J Pharmacol Exp Ther; 1996 Sep; 278(3):1006-11. PubMed ID: 8819479
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of recombinant human tumor necrosis factor-alpha in rats. Effects of size and number of doses and nephrectomy.
Ferraiolo BL; McCabe J; Hollenbach S; Hultgren B; Pitti R; Wilking H
Drug Metab Dispos; 1989; 17(4):369-72. PubMed ID: 2571474
[TBL] [Abstract][Full Text] [Related]
12. Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency.
Tsutsumi Y; Kihira T; Tsunoda S; Kanamori T; Nakagawa S; Mayumi T
Br J Cancer; 1995 May; 71(5):963-8. PubMed ID: 7734321
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-alpha in mice.
Ferraiolo BL; Moore JA; Crase D; Gribling P; Wilking H; Baughman RA
Drug Metab Dispos; 1988; 16(2):270-5. PubMed ID: 2898346
[TBL] [Abstract][Full Text] [Related]
14. Effects of monoclonal antibody, recombinant interferon-gamma, and tumor necrosis factor-alpha in the treatment of human melanoma xenografts.
Gridley DS; Slater JM; Stickney DR
J Biol Response Mod; 1989 Dec; 8(6):593-602. PubMed ID: 2513378
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory and toxic effects of free and liposome-encapsulated tumor necrosis factor alpha in rats.
Debs RJ; Fuchs HJ; Philip R; Brunette EN; Düzgüneş N; Shellito JE; Liggitt D; Patton JR
Cancer Res; 1990 Jan; 50(2):375-80. PubMed ID: 2295077
[TBL] [Abstract][Full Text] [Related]
16. The effect of combining recombinant human tumor necrosis factor-alpha with local radiation on tumor control probability of a human glioblastoma multiforme xenograft in nude mice.
Huang P; Allam A; Perez LA; Taghian A; Freeman J; Suit HD
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):93-8. PubMed ID: 7721643
[TBL] [Abstract][Full Text] [Related]
17. Regulation of neutrophil migration and superoxide production by recombinant tumor necrosis factors-alpha and -beta: comparison to recombinant interferon-gamma and interleukin-1 alpha.
Figari IS; Mori NA; Palladino MA
Blood; 1987 Oct; 70(4):979-84. PubMed ID: 2820532
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity.
Palladino MA; Shalaby MR; Kramer SM; Ferraiolo BL; Baughman RA; Deleo AB; Crase D; Marafino B; Aggarwal BB; Figari IS
J Immunol; 1987 Jun; 138(11):4023-32. PubMed ID: 3295044
[TBL] [Abstract][Full Text] [Related]
19. Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency.
Yoshioka Y; Tsutsumi Y; Ikemizu S; Yamamoto Y; Shibata H; Nishibata T; Mukai Y; Okamoto T; Taniai M; Kawamura M; Abe Y; Nakagawa S; Nagata S; Yamagata Y; Mayumi T
Biochem Biophys Res Commun; 2004 Mar; 315(4):808-14. PubMed ID: 14985084
[TBL] [Abstract][Full Text] [Related]
20. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
